Importance of intra-therapy single-photon emission tomographic imaging in calculating tumour dosimetry for a lymphoma patient
dc.contributor.author | Kaminski, Mark S. | en_US |
dc.contributor.author | Wahl, Richard L. | en_US |
dc.contributor.author | Koral, Kenneth F. | en_US |
dc.contributor.author | Francis, Isaac R. | en_US |
dc.contributor.author | Zasadny, Kenneth R. | en_US |
dc.contributor.author | Swailem, Fayez M. | en_US |
dc.contributor.author | Buchbinder, Steven F. | en_US |
dc.date.accessioned | 2006-09-11T18:15:27Z | |
dc.date.available | 2006-09-11T18:15:27Z | |
dc.date.issued | 1991-06 | en_US |
dc.identifier.citation | Koral, Kenneth F.; Zasadny, Kenneth R.; Swailem, Fayez M.; Buchbinder, Steven F.; Francis, Isaac R.; Kaminski, Mark S.; Wahl, Richard L.; (1991). "Importance of intra-therapy single-photon emission tomographic imaging in calculating tumour dosimetry for a lymphoma patient." European Journal of Nuclear Medicine 18(6): 432-435. <http://hdl.handle.net/2027.42/46832> | en_US |
dc.identifier.issn | 1619-7089 | en_US |
dc.identifier.issn | 0340-6997 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/46832 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=1879448&dopt=citation | en_US |
dc.description.abstract | The dosimetry for two, similarly sized tumours in a lymphoma patient being treated with non-bone marrow ablative, monoclonal antibody therapy is reported. The 45-year-old man was infused with 2.48 GBq (67 mCi) of 131 I-labelled MB-1. Prior to therapy, a time series of diagnostic conjugate-view images and a radionuclide transmission scan were obtained and processed to obtain time-activity curves. Starting 2 days after the therapeutic infusion of radioactivity, a second conjugate-view time series was obtained. At that time, a quantitative single-photon emission tomography (SPET) acquisition was also carried out. Pre- and post-therapy X-ray computed tomography scans demonstrated a percentage reduction in volume for the right tumour which was 3.8 times that for the left tumour. In contrast, diagnostic conjugate views by themselves estimated the absorbed dose to be the same for the two tumours. Addition of therapy conjugate-view data increased the right-over-left ratio but only to 1.22. Normalizing either time-activity series by the intra-therapy SPET results increased the ratio to greater than 1.5. We assume here that a differential dose is correct according to the differential tumour shirnkage. One can further assume that the largest ratio corresponds most certainly to the most accurate dosimetric method. Other assumptions are possible. While additional study is essential, data from this patient suggest that the preferred dosimetric method is intra-therapy SPET normalization of either time series. | en_US |
dc.format.extent | 412882 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Tumour Dosimetry | en_US |
dc.subject.other | Lymphoma | en_US |
dc.subject.other | Nuclear Medicine | en_US |
dc.subject.other | Imaging / Radiology | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Single-photon Emission Tomography (SPET) Quantification | en_US |
dc.subject.other | Monoclonal Antibody | en_US |
dc.subject.other | Radionuclide Therapy | en_US |
dc.title | Importance of intra-therapy single-photon emission tomographic imaging in calculating tumour dosimetry for a lymphoma patient | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Physics | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Radiology, University of Michigan, B16412 0028, 48109, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Department of Internal Medicine, Nuclear Medicine Division, B16412 0028, 48109, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Department of Internal Medicine, Nuclear Medicine Division, B16412 0028, 48109, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Department of Internal Medicine, Nuclear Medicine Division, B16412 0028, 48109, Ann Arbor, MI, USA; V.A. Medical Center, 85723, Tucson, AZ, USA | en_US |
dc.contributor.affiliationother | Department of Internal Medicine, Nuclear Medicine Division, B16412 0028, 48109, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Department of Internal Medicine, Nuclear Medicine Division, B16412 0028, 48109, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Department of Internal Medicine, Nuclear Medicine Division, B16412 0028, 48109, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 1879448 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/46832/1/259_2005_Article_BF02258433.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF02258433 | en_US |
dc.identifier.source | European Journal of Nuclear Medicine | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.